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Abstract
Background: Colorectal cancer is the second commonest cause of cancer death and the cost to primary care has not been 
estimated.
Aim: To determine the direct primary care costs of colorectal cancer care.
Design: Retrospective case note review.
Setting: Nottingham, United Kingdom.
Methods: We identiﬁ  ed people with colorectal cancer between 1995 and 1998, from computerised pathology records. 
Colorectal cancer related resources consumed in primary care, from hospital discharge to death, were identiﬁ  ed from 
retrospective notes review. Outcome measures were costs incurred by the General Practitioner (GP) and the total cost to 
primary care. We used multiple linear regression to identify predictors of cost.
Results: Of 416 people identiﬁ  ed from pathology records, the median age at primary operation of the 135 (33%) people we 
selected was 74.2 (IQR 14.4) years, 75 (56%) were male. The median GP cost was: Dukes A £61.0 (IQR 516.2) and Dukes 
D £936.2 (1196.2) p   0.01. The geometric mean ratio found Dukes D cancers to be 10 times as costly as Dukes A. The 
median total cost was: Dukes A £1038.3 (IQR 5090.6) and Dukes D £1815.2 (2092.5) p = 0.06. Using multivariate analysis, 
Dukes stage was the most important predictor of GP costs. For total costs, the presence of a permanent stoma was the most 
predictive variable, followed by adjuvant therapy and advanced Dukes stage (Dukes C and D).
Conclusions: Contrary to hospital based care costs, late stage disease (Dukes D) costs substantially more to general practice 
than any other stage. Stoma care products are the most costly prescribable item. Costs savings may be realised in primary 
care by screening detection of early stage colorectal cancers.
Keywords: colorectal cancer, cost, general practice, Dukes stage, stoma
Introduction
Colorectal cancer remains the second commonest cause of cancer death in the U.K. and consumes 
signiﬁ  cant resources within both primary and secondary care.
1 Previous studies have looked at the costs 
of hospital based care, ﬁ  nding the costs of very early and very late stage cancers to be signiﬁ  cantly 
lower than those of treating cancers in the intermediate stages.
2 However, there is scarce information 
on the resources consumed by treated colorectal cancer patients following hospital discharge. The 
resource consumption of this common cancer may be considerable and costly so our aim, in this 
retrospective study, was to establish the cost that treated colorectal cancer incurred on primary care.
Methods
Study population
We identiﬁ  ed people with histologically proven colorectal cancer, treated at one hospital between 1995 
and 1998, from computerised pathology records. People identiﬁ  ed as deceased, had their notes reviewed 2
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by a single investigator (DM) at the local health 
authority. A small group of people still alive (n = 8) 
and registered with two GP practices, also had their 
notes reviewed. The study time period was from 
hospital discharge following excision of the 
primary cancer until death or the study end date 
(01/01/2003). We excluded those patients who died 
in the early post-operative period (30 days) without 
being discharged home, as they had consumed no 
community resources. Ethical approval was 
obtained for the study (LREC Q1110208).
Costs
Our main outcomes were costs incurred by the 
General Practitioner (GP) and the total cost to 
primary care. We included resources consumed in 
primary care and related to colorectal cancer and 
excluded costs due to benign gastrointestinal 
symptoms (e.g. constipation). GP costs included 
all GP related activity (e.g. home visits) or prescrib-
ing. Total cost to primary care, included all iden-
tiﬁ  able costs related to colorectal cancer care (e.g. 
district nurse, stoma care products) in addition to 
the GP costs. The cost of training a GP was con-
sidered when costing their time (qualification 
costs) and a 5% discount rate was chosen for costs 
in the main analysis. We used standard sources to 
calculate costs,
3–7 which were then extrapolated to 
2002 prices, using the Gross Domestic Product 
deﬂ  ator.
8 Drugs prescribed by GP’s were costed 
for a one month supply. An estimated cost (£1500) 
of yearly stoma care products was included in the 
calculation of total cost, based on each person using 
2 stoma bags per day at a unit cost of £2, plus other 
occasional consumables.
Statistical analysis
Initially we described the characteristics and cost 
data by Dukes stage of disease using median values, 
interquartile ranges and non-parametric tests where 
appropriate, as the cost data was non-normal. We 
used a non-parametric test for trend
9 to examine 
trends across Dukes stage. We excluded 5 subjects 
from the regression analysis who had incurred no 
primary care cost and so were considered outliers. 
Following loge transformation of costs, multiple 
linear regression (backward variable elimination 
technique) was used to estimate the best predictors of 
primary care costs. Sensitivity analysis was performed 
across the three different GP costs structures, cost 
of stoma care (between £1000 and £2000) and through 
a range of discounting rates (0%–10%). Analyses 
were performed in Stata 7.0 (Stata Corporation, 
Texas).
Results
Of 416 people identiﬁ  ed from pathology records, 
127 were deceased. Within two GP practices, 
8 people still alive had their notes reviewed. 
Overall, 22 (5%) subjects were excluded due to 
death in the peri-operative period. The median age 
at primary operation, of the 135 (33%) people 
included, was 74.2 (IQR 14.4) years, 75 (56%) 
were male and 112 (83%) of primary operations 
were considered curative. The median time from 
operation to death or end date was 2.1 years 
(IQR 2.4); those with a Dukes A cancer surviving 
longest—3.1 years (IQR 2.1); Dukes D surviving 
least long −0.8 years (IQR 0.9). The proportion of 
people dying from colorectal cancer increased 
across stage  –11% in Dukes A and 95% in Dukes D 
(Table 1).
Table 2 presents the GP costs and total costs by 
various demographic, disease and treatment char-
acteristics. There were large differences in GP cost 
across Dukes stage, which showed a trend of rising 
costs with more advanced disease (Dukes D versus 
Dukes A was £936.2 vs. £61.0; p   0.01). 
The pattern was similar, although not statistically 
signiﬁ  cant, for total cost (Dukes D versus Dukes A 
was £1815.2 vs. £1038.3; p = 0.06). People 
aged 75 years or over at operation incurred less costs 
than those under 75: £351.8 vs. £669.6 (p = 0.01); 
total costs were £926.0 vs. £1608.9 (p   0.01). 
Having a permanent stoma, although not statisti-
cally signiﬁ  cant in the cost of GP care, had a large 
effect on total cost. Cost of managing a permanent 
stoma versus no stoma was £3766.3 vs. £664.9 
(p   0.05). Sensitivity analysis was performed, 
varying the cost structure, stoma care costs and the 
discounting rate but this made no difference to the 
overall conclusions.
Table 3 illustrates the effect of various 
characteristics on cost, when selected using 
backward elimination regression analysis. Dukes 
stage and adjuvant therapy were the only variables 
that remained in the model for GP costs, which 
rose incrementally with advancing stage. Once 
adjusted for adjuvant therapy, the ratio of the 
geometric mean GP cost of people with Dukes D 
cancer compared to Dukes A was 10:1 (95% 
CI 4.0–25.0). When we analysed total cost, Dukes 3
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stage appeared to be less important in contrast to 
having a permanent stoma where costs versus no 
stoma were 7-fold more expensive (geometric 
mean ratio 7.4 (95% CI 5.0–11.0)). The total cost 
of a Dukes D cancer was twice that of Dukes A 
(geometric mean ratio 2.2 (95% CI 1.2–3.8)).
Discussion
Findings
We found that Dukes stage was the most important 
determinant of GP costs in those treated for 
colorectal cancer, with Dukes D cancers costing 
approximately ten times as much as Dukes A 
cancers. The trend of rising cost with advancing 
stage seen in this study, has not been observed in 
hospital based care where very early and very late 
stage conferred least costs. In contrast, Dukes 
stage appeared less important than the presence 
of a permanent stoma when calculating total cost 
to primary care, probably because of the expense 
and consistent requirement of stoma products 
(£1500–£2000 per annum). However, on average, 
a Dukes D cancer still cost £777 more than a 
Dukes A cancer.
Strengths and limitations
Reviewing the notes of deceased patients limited 
our study population to a more advanced stage of 
disease with a reduced life expectancy but ensured 
an accurate end point for costs. The eight alive 
patients included were the result of the pilot period 
of this study and were therefore part of the 
study design. When excluded, the high propor-
tion of permanent stomas in the small group of 
Dukes A cancers (50%) and their long survival 
period (median 3.8 years) caused the total costs 
of Dukes A to be higher than any other—£3043.8 
(IQR 5628.1). Notwithstanding this, the cost of 
Dukes A to the GP remained minimal, total costs 
for Dukes B and C remained over £670 cheaper 
than Dukes D. When costs were annualised, the 
cost per life year showed an even greater trend of 
rising cost with advancing stage. As most recur-
rences occur within two years study time period 
provided up to 8 years of follow up
10 we would 
expect that any recurrent disease had been detected 
and therefore costed.
Although irresectable (often advanced stage) 
disease is one indication for a permanent stoma, the 
decision is also often dependent on the site of the 
lesion. Regular stoma care products are required 
for those with permanent stomas, yet the results of 
GP costs indicate that this cost is rarely documented. 
Estimated costs were required due to the lack of 
documentary evidence and minimal economic data 
in the medical literature. We used a ﬁ  gure of £1500 
which assumes the use of two bags per day plus 
additional consumables, an estimate deemed rea-
sonable by an experienced stoma care nurse 
(personal communication Ms. J. Watts). When we 
varied the annual stoma cost by £1000 it made no 
difference to the overall conclusions of our study.
Identifying actual resource use is a more robust 
and accurate method of economic analysis than 
economic modelling but it is time-consuming and 
expensive. Economic modelling must estimate 
resource consumption but in doing so, makes 
assumptions of use and costs. Our study reduced 
the number of such assumptions that had to be 
made.
Hospital based follow up during the 1990’s 
would probably be considered less protocol driven 
in the U.K. than it is today. CEA measurements 
Table 1. Characteristics of the 135 patients within the study group by Dukes stage.
Dukes stage of disease
A
(n = 9)
B
(n = 34)
C
(n = 73)
D
(n = 19)
Male n (%) 5 (56) 17 (50) 38 (52) 15 (79)
Age at operation Years (IQR) 75.5 (15.6) 77.0 (9.9) 72.9 (14.8) 71.5 (15.8)
Permanent stoma required n (%) 4 (44) 11 (32) 16 (22) 9 (47)
Intensive nursing required n (%) 1 (11) 3 (9) 4 (6) 1 (5)
Adjuvant therapy required n (%) 2 (25) 11 (32) 40 (55) 7 (37)
Deaths from colorectal cancer n (%) 1 (11) 15 (44) 56 (77) 18 (95)4
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whether in hospital or primary care were not 
routinely used (and in certain institutions would 
remain debatable). USS surveillance for liver 
metastases has been superceded by CT Chest, 
Abdomen and Pelvis surveillance, although the 
frequency of tests (including colonoscopy) has 
perhaps reduced. Generally, in Nottingham at the 
time, follow up was hospital based under the 
original consultant. It was not possible to review 
the travel expenses aspect and a future study of the 
patient costs incurred would be useful.
Who should perform the follow up and how 
intensively remain hotly debated issues but studies 
have shown that primary care can perform this role 
although the research is perhaps slightly dated.
11 
Renehan et al. concluded from a meta-analysis of 
intensive hospital based follow up that “based on 
the available data and current costs, intensive 
follow up after curative resection for colorectal 
cancer is economically justiﬁ  ed and should be 
normal practice.”
12 As with any meta-analysis 
there must be a degree of caution in potentially 
costly decisions. A Norwegian trial of systematic 
follow up found that follow-up program did not 
inﬂ  uence cancer-speciﬁ  c survival, that overall 
compliance with the surveillance program was 
66% and the total program cost was 20,530 euro 
(U.S. 25,289 dollars) for one surviving patient after 
surgery for recurrence.
13 In a study by our unit, a 
simulated intensive follow up programme would 
detect considerably more resectable recurrences 
but the ﬁ  nancial cost and resource requirements 
would be considerable. Resource limitations, the 
introduction of screening and continuing NHS 
deﬁ  cits may mean that the most intensive follow 
up will need to be tailored to those with the highest 
likelihood of recurrent CRC.
14
We have only dealt with costs related to 
colorectal cancer but we may have underestimated 
the palliative care costs due to the limited docu-
mentation of District and other Nurse activity in 
GP records. In palliative care settings, 71.6% of 
Table 3. Univariate and Multivariate analysis by GP and total costs.
Ratio of geometric mean (95% conﬁ  dence interval)
Dependent variable Univariate Multivariate**
GP costs
Dukes A* 1 1
Dukes B 3.7 (1.5–8.8) 3.7 (1.6–8.7)
Dukes C 5.4 (2.4–12.2) 4.8 (2.1–10.7)
Dukes D 10.2 (4.0–26.0) 10.0 (4.0–25.0)
Adjuvant therapy
No* 1 1
Yes 1.8 (1.2–2.8) 1.7 (1.1–2.6)
Total costs
Dukes A* 1 1
Dukes B 1.4 (0.5–3.8) Omitted by model
Dukes C 2.0 (0.8–5.3) 1.5 (2.0–6.0)
Dukes D 3.6 (1.2–10.9) 2.2 (1.2–3.8)
Stoma formed
No* 1 1
Temporary 3.9 (2.2–6.7) 3.5 (2.0–6.0)
Permanent 7.7 (5.1–11.6) 7.4 (5.0–11.0)
Adjuvant therapy
No* 1 1
Yes 1.7 (1.1–2.8) 1.5 (1.0–2.1)
*Baseline category.
**Backward stepwise linear regression.6
Macafee et al
Clinical Medicine: Oncology 2009:3
patients require District nurse input with only 10% 
utilising GP’s and home helps.
3 In addition, having 
taken a health service perspective rather than a 
patient (or societal) viewpoint we have had to 
ignore costs that are subsequently transferred from 
hospital care to the patient and his/her household.
15 
Mean patient and carer costs of between £404 to 
£914 have been found in those undergoing 
palliative chemotherapy, whilst the mean total 
primary care costs in the same study were only 
£114–£152.
16 If such costs had been included, the 
trend of rising total costs with advancing stage 
might have been more striking.
Implications
Subjects successfully operated for an early stage 
colorectal cancer without the creation of a stoma, 
had minimal ongoing primary care costs. Advanced 
stage disease or a permanent stoma required sub-
stantial resource allocation and despite overlooking 
patient and carer costs, advanced stage disease cost 
primary care £900 per year more than earlier stage 
cancers. This is a considerable cost and should be 
considered when apportioning resources.
Ours is the ﬁ  rst study that has looked at the 
primary care costs for treated colorectal cancer. 
From a hospital perspective, it is often considered 
that Dukes D confers minimal cost due to reduced 
life expectancy but this study has shown this to be 
an unreliable assumption. While hospital costs may 
be low, primary care costs are generally higher. 
Reducing the number of permanent stomas may 
be helped by modern surgical techniques and sta-
pling devices, which enable very low rectal anas-
tomoses and ileo-anal pouch formations. 
Identifying earlier stage disease can be achieved 
by screening, conﬁ  rmed recently in the national 
FOBT pilot screening program,
17 so reducing the 
costs of advanced disease to primary care.
Where this Piece Fits?
There are over 34,000 new cases of colorectal 
cancer in the U.K. per year, costing over £300 
million in surgical, oncological and palliative 
care services. Previous hospital based studies 
have found Dukes A and D cancers to cost less 
than intermediate stage cancers but the cost to 
primary care has not been established and is 
likely to be considerable. Our study found that 
GP costs increased with advancing stage. Stoma 
care products also added signiﬁ  cantly to primary 
care costs but were independent of stage. Costs 
savings may be realised in primary care by 
screening detection of early stage colorectal 
cancers.
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